{"gene":"UBLCP1","run_date":"2026-06-10T10:51:56","timeline":{"discoveries":[{"year":2011,"finding":"UBLCP1 directly interacts with the 26S proteasome via its UBL domain and is exclusively localized in the nucleus. It dephosphorylates the 26S proteasome and inhibits proteasome activity in vitro. Knockdown of UBLCP1 in cells promotes 26S proteasome assembly and selectively enhances nuclear proteasome activity.","method":"Co-immunoprecipitation, in vitro phosphatase assay, siRNA knockdown with proteasome activity readout, nuclear localization by fractionation/imaging","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — in vitro enzymatic assay plus domain-mapping pulldown plus cellular KD with specific nuclear proteasome activity readout; foundational study by Dixon lab","pmids":["21949367"],"is_preprint":false},{"year":2013,"finding":"NMR solution structure of the UBL domain of human UBLCP1 was determined; the domain contains a unique β3 strand and β3-α2 loop (instead of the canonical β4), and the positively charged residues of the β3-α2 loop mediate interaction with the C-terminal leucine-rich repeat-like domain of Rpn1 (a 19S regulatory particle subunit).","method":"NMR spectroscopy (high-resolution solution structure), backbone dynamics analysis, binding interaction mapping","journal":"PloS one","confidence":"High","confidence_rationale":"Tier 1 / Moderate — high-resolution NMR structure with functional binding validation in single study","pmids":["23667555"],"is_preprint":false},{"year":2019,"finding":"UBLCP1 acts as the proteasome-resident phosphatase that dephosphorylates Ser361 of Rpn1 (a 19S base subunit); PIM1/2/3 kinases phosphorylate Rpn1-S361, and UBLCP1 reverses this modification. Rpn1-S361 phosphorylation is required for proper 26S proteasome assembly, and loss of UBLCP1-regulated dephosphorylation alters this assembly step.","method":"CRISPR/Cas9 gene editing, quantitative mass spectrometry, human kinome screen, genetic code expansion for site-specific phosphorylation, co-immunoprecipitation of precursor complexes","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — multiple orthogonal methods (CRISPR, MS, kinome screen, genetic code expansion) establishing writer/eraser identity and mechanistic consequence for assembly","pmids":["31843888"],"is_preprint":false},{"year":2005,"finding":"UBLCP1 contains a UBL domain and a CTD phosphatase domain, is localized in the nucleus, and can dephosphorylate GST-tagged RNA polymerase II CTD in vitro.","method":"Transient transfection with subcellular localization imaging (COS-7 cells), in vitro phosphatase assay with GST-CTD substrate","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 1–3 / Weak — in vitro phosphatase activity shown but single lab, limited mechanistic follow-up; nuclear localization by transfection imaging","pmids":["15883030"],"is_preprint":false},{"year":2015,"finding":"A small-molecule inhibitor (compound 13, IC50 = 1.0 µM) targeting both the UBLCP1 phosphatase active site and an adjacent binding pocket selectively inhibits UBLCP1 and, in cells, inhibits UBLCP1 function and upregulates nuclear proteasome activity.","method":"Salicylic acid fragment-based library screening, IC50 determination, selectivity panel against multiple phosphatase families, cellular proteasome activity assay","journal":"Bioorganic & medicinal chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — active-site-directed inhibitor with selectivity profiling and cellular functional readout, single lab","pmids":["25907364"],"is_preprint":false},{"year":2020,"finding":"UBLCP1, via its UBL domain, activates latent 26S proteasomes by stimulating peptide hydrolysis two- to fivefold; the UBL domain is specifically required for the increase in ATPase activity, while peptide hydrolysis stimulation can also occur independent of the UBL domain.","method":"In vitro proteasome activity assays (peptide hydrolysis, ATPase), UBL domain deletion constructs, purified protein reconstitution","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro reconstitution with domain-deletion mutagenesis, multiple activity readouts, single lab","pmids":["32071216"],"is_preprint":false},{"year":2023,"finding":"A truncating deletion in UBLCP1 exon 10 (generating a premature stop codon in the phosphatase domain) leads to decreased UBLCP1 protein expression, increased proteasome activity, decreased ubiquitinated protein levels, and downregulation of other proteasome subunits in patient-derived fibroblasts. Restoration of full-length UBLCP1 via gentamicin-promoted read-through rescues function.","method":"Whole exome sequencing, patient-derived fibroblast functional assays, proteasome activity assay, ubiquitinated protein levels, MG132 rescue experiment, gentamicin read-through restoration","journal":"Translational psychiatry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — patient-derived loss-of-function with multiple biochemical readouts and pharmacological rescue, single study","pmids":["38129378"],"is_preprint":false},{"year":2024,"finding":"Ublcp1 was identified as an iCrMN (induced cranial motor neuron)-specific regulator of nuclear 26S proteasome activity; cranial motor neurons express higher levels of Ublcp1 relative to spinal motor neurons and show higher 26S (but not 20S) proteasome activity.","method":"Quantitative transcriptome and proteome profiling of induced motor neurons, 26S vs 20S proteasome activity assays, cell-type comparison","journal":"Cell reports","confidence":"Medium","confidence_rationale":"Tier 2–3 / Weak — proteasome activity assay in cell-type comparison with Ublcp1 identified as regulator, single study, limited mechanistic follow-up of UBLCP1 specifically","pmids":["38457337"],"is_preprint":false}],"current_model":"UBLCP1 is a nuclear phosphatase that binds the 26S proteasome via its UBL domain (which contacts the Rpn1 subunit) and inhibits proteasome activity by dephosphorylating key regulatory phosphosites including Rpn1-Ser361, thereby restraining 26S assembly and nuclear proteasome activity; paradoxically, its UBL domain can also directly activate latent proteasomes by stimulating both peptide hydrolysis and ATPase activity."},"narrative":{"mechanistic_narrative":"UBLCP1 is a nuclear proteasome-resident phosphatase that restrains nuclear 26S proteasome activity by dephosphorylating regulatory phosphosites on the 19S regulatory particle [PMID:21949367]. It engages the proteasome through its UBL domain, whose unique β3 strand and positively charged β3-α2 loop directly contact the C-terminal leucine-rich repeat-like domain of the Rpn1 subunit [PMID:23667555]. Mechanistically, UBLCP1 functions as the eraser for Rpn1-Ser361, a site written by PIM1/2/3 kinases that is required for proper 26S assembly; by reversing this phosphorylation UBLCP1 antagonizes 26S assembly, and its depletion promotes assembly and selectively enhances nuclear proteasome activity [PMID:21949367, PMID:31843888]. The catalytic CTD phosphatase domain can also dephosphorylate the RNA polymerase II CTD in vitro [PMID:15883030]. Paradoxically, the UBL domain directly stimulates latent 26S proteasomes, increasing peptide hydrolysis two- to fivefold and being specifically required for stimulation of ATPase activity, indicating a dual regulatory output beyond its phosphatase activity [PMID:32071216]. A small-molecule inhibitor targeting the phosphatase active site and an adjacent pocket selectively blocks UBLCP1 and upregulates nuclear proteasome activity in cells [PMID:25907364]. A truncating UBLCP1 deletion in patient-derived fibroblasts reduces UBLCP1 protein, elevates proteasome activity, and lowers ubiquitinated protein levels, with read-through restoration rescuing function, linking loss of UBLCP1 to a human phenotype [PMID:38129378].","teleology":[{"year":2005,"claim":"Established UBLCP1's domain architecture and catalytic potential before its physiological substrate was known, identifying a nuclear protein combining a UBL domain with a CTD phosphatase domain capable of dephosphorylating RNA Pol II CTD in vitro.","evidence":"Subcellular localization imaging in COS-7 cells and in vitro phosphatase assay with GST-CTD substrate","pmids":["15883030"],"confidence":"Medium","gaps":["RNA Pol II CTD demonstrated only in vitro, with no cellular substrate established","no link to the proteasome at this stage"]},{"year":2011,"claim":"Defined UBLCP1's core function as a nuclear proteasome phosphatase that negatively regulates nuclear 26S proteasome activity and assembly, resolving what its phosphatase activity acts upon physiologically.","evidence":"Co-immunoprecipitation, in vitro phosphatase assay, siRNA knockdown with nuclear proteasome activity readout, and nuclear localization by fractionation/imaging","pmids":["21949367"],"confidence":"High","gaps":["specific proteasome phosphosite substrate not yet identified","structural basis of UBL-proteasome contact not defined"]},{"year":2013,"claim":"Provided the structural basis for proteasome engagement, showing how a non-canonical UBL fold uses a charged β3-α2 loop to bind a specific 19S subunit.","evidence":"High-resolution NMR solution structure of the UBL domain with binding interaction mapping to Rpn1 LRR-like domain","pmids":["23667555"],"confidence":"High","gaps":["full-length enzyme-proteasome complex structure not determined","does not address how binding positions the catalytic domain on its substrate"]},{"year":2015,"claim":"Demonstrated UBLCP1 is pharmacologically tractable and confirmed its inhibitory role on nuclear proteasome activity in cells through chemical inhibition.","evidence":"Fragment-based screening yielding an active-site/adjacent-pocket inhibitor, selectivity profiling, and cellular proteasome activity assay","pmids":["25907364"],"confidence":"Medium","gaps":["single lab","no in vivo validation of the inhibitor"]},{"year":2019,"claim":"Identified the precise phospho-substrate and the writer/eraser logic, establishing Rpn1-Ser361 as the UBLCP1 dephosphorylation target reversing PIM kinase phosphorylation to control 26S assembly.","evidence":"CRISPR/Cas9 editing, quantitative mass spectrometry, human kinome screen, genetic code expansion for site-specific phosphorylation, and Co-IP of precursor complexes","pmids":["31843888"],"confidence":"High","gaps":["whether additional proteasome phosphosites are UBLCP1 substrates not resolved","in vivo physiological context of the PIM-UBLCP1 axis not addressed"]},{"year":2020,"claim":"Revealed a paradoxical second activity, showing the UBL domain directly stimulates latent proteasome peptide hydrolysis and is specifically required for ATPase stimulation, decoupling proteasome activation from the phosphatase function.","evidence":"In vitro peptide hydrolysis and ATPase assays with UBL domain deletion constructs and purified protein reconstitution","pmids":["32071216"],"confidence":"High","gaps":["how phosphatase-dependent inhibition and UBL-dependent activation are reconciled in cells not resolved","single lab in vitro reconstitution"]},{"year":2023,"claim":"Linked UBLCP1 loss of function to a human disease phenotype, showing a truncating deletion reduces protein, elevates proteasome activity, and is rescuable by read-through.","evidence":"Whole exome sequencing and patient-derived fibroblast functional assays with gentamicin read-through restoration","pmids":["38129378"],"confidence":"Medium","gaps":["single study","genotype-phenotype causality at the organismal level not fully established"]},{"year":2024,"claim":"Placed UBLCP1 in a cell-type-specific context, identifying it as a cranial motor neuron-specific regulator that tunes nuclear 26S (not 20S) proteasome activity.","evidence":"Quantitative transcriptome/proteome profiling of induced motor neurons and 26S vs 20S proteasome activity comparison","pmids":["38457337"],"confidence":"Medium","gaps":["mechanistic basis of cell-type selectivity not defined","limited mechanistic follow-up specific to UBLCP1"]},{"year":null,"claim":"How the inhibitory phosphatase activity and the activating UBL-domain function are integrated to set net nuclear proteasome output in a physiological cell context remains unresolved.","evidence":"","pmids":[],"confidence":"High","gaps":["no model reconciling dual inhibitory/activating outputs in vivo","regulation of UBLCP1 itself (upstream signals controlling its activity) uncharacterized","full enzyme-proteasome complex structure not determined"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0016787","term_label":"hydrolase activity","supporting_discovery_ids":[0,2,3]},{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[0,2,3]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[0,5]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[0,3]}],"pathway":[{"term_id":"R-HSA-392499","term_label":"Metabolism of proteins","supporting_discovery_ids":[0,2]}],"complexes":["26S proteasome"],"partners":["PSMD2","PIM1","PIM2","PIM3"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q8WVY7","full_name":"Ubiquitin-like domain-containing CTD phosphatase 1","aliases":["Nuclear proteasome inhibitor UBLCP1"],"length_aa":318,"mass_kda":36.8,"function":"Dephosphorylates 26S nuclear proteasomes, thereby decreasing their proteolytic activity (PubMed:21949367, PubMed:28539385). Recruited to the 19S regulatory particle of the 26S proteasome through its interaction with 19S component PSMD2/RPN1 (PubMed:28539385). Once recruited, dephosphorylates 19S component PSMC2/RPT1 which impairs PSMC2 ATPase activity and disrupts 26S proteasome assembly (PubMed:28539385). Has also been reported to stimulate the proteolytic activity of the 26S proteasome (PubMed:32071216)","subcellular_location":"Nucleus","url":"https://www.uniprot.org/uniprotkb/Q8WVY7/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/UBLCP1","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/UBLCP1","total_profiled":1310},"omim":[{"mim_id":"609867","title":"UBIQUITIN-LIKE DOMAIN-CONTAINING CTD PHOSPHATASE 1; UBLCP1","url":"https://www.omim.org/entry/609867"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Nucleoplasm","reliability":"Supported"},{"location":"Nucleoli","reliability":"Supported"},{"location":"Nucleoli rim","reliability":"Supported"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/UBLCP1"},"hgnc":{"alias_symbol":["MGC10067","CPUB1"],"prev_symbol":[]},"alphafold":{"accession":"Q8WVY7","domains":[{"cath_id":"3.10.20.90","chopping":"4-78","consensus_level":"high","plddt":90.888,"start":4,"end":78},{"cath_id":"3.40.50.1000","chopping":"111-316","consensus_level":"high","plddt":95.532,"start":111,"end":316}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q8WVY7","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q8WVY7-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q8WVY7-F1-predicted_aligned_error_v6.png","plddt_mean":90.25},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=UBLCP1","jax_strain_url":"https://www.jax.org/strain/search?query=UBLCP1"},"sequence":{"accession":"Q8WVY7","fasta_url":"https://rest.uniprot.org/uniprotkb/Q8WVY7.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q8WVY7/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q8WVY7"}},"corpus_meta":[{"pmid":"21949367","id":"PMC_21949367","title":"UBLCP1 is a 26S proteasome phosphatase that regulates nuclear proteasome activity.","date":"2011","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/21949367","citation_count":65,"is_preprint":false},{"pmid":"30167433","id":"PMC_30167433","title":"Influence of Genetic Polymorphism Towards Pulmonary Tuberculosis Susceptibility.","date":"2018","source":"Frontiers in medicine","url":"https://pubmed.ncbi.nlm.nih.gov/30167433","citation_count":60,"is_preprint":false},{"pmid":"26942285","id":"PMC_26942285","title":"A Locus at 5q33.3 Confers Resistance to Tuberculosis in Highly Susceptible Individuals.","date":"2016","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/26942285","citation_count":60,"is_preprint":false},{"pmid":"32071216","id":"PMC_32071216","title":"Proteins containing ubiquitin-like (Ubl) domains not only bind to 26S proteasomes but also induce their activation.","date":"2020","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/32071216","citation_count":55,"is_preprint":false},{"pmid":"24376564","id":"PMC_24376564","title":"RAPID-SELEX for RNA aptamers.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/24376564","citation_count":48,"is_preprint":false},{"pmid":"31843888","id":"PMC_31843888","title":"Reversible phosphorylation of Rpn1 regulates 26S proteasome assembly and function.","date":"2019","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/31843888","citation_count":46,"is_preprint":false},{"pmid":"15883030","id":"PMC_15883030","title":"Cloning and characterization of a novel RNA polymerase II C-terminal domain phosphatase.","date":"2005","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/15883030","citation_count":23,"is_preprint":false},{"pmid":"32862155","id":"PMC_32862155","title":"Human genetic background in susceptibility to tuberculosis.","date":"2020","source":"International journal of mycobacteriology","url":"https://pubmed.ncbi.nlm.nih.gov/32862155","citation_count":21,"is_preprint":false},{"pmid":"35501893","id":"PMC_35501893","title":"Transcriptomic underpinnings of high and low mirror aggression zebrafish behaviours.","date":"2022","source":"BMC biology","url":"https://pubmed.ncbi.nlm.nih.gov/35501893","citation_count":16,"is_preprint":false},{"pmid":"29490353","id":"PMC_29490353","title":"Association of Long Noncoding RNAs Polymorphisms With Ankylosing Spondylitis, Vogt-Koyanagi-Harada Disease, and Behcet's Disease.","date":"2018","source":"Investigative ophthalmology & visual science","url":"https://pubmed.ncbi.nlm.nih.gov/29490353","citation_count":13,"is_preprint":false},{"pmid":"25907364","id":"PMC_25907364","title":"A potent and selective inhibitor for the UBLCP1 proteasome phosphatase.","date":"2015","source":"Bioorganic & medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/25907364","citation_count":12,"is_preprint":false},{"pmid":"34409462","id":"PMC_34409462","title":"A transcriptome-wide association study identifies novel susceptibility genes for psoriasis.","date":"2021","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/34409462","citation_count":11,"is_preprint":false},{"pmid":"23667555","id":"PMC_23667555","title":"Solution structure and Rpn1 interaction of the UBL domain of human RNA polymerase II C-terminal domain phosphatase.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/23667555","citation_count":7,"is_preprint":false},{"pmid":"35756599","id":"PMC_35756599","title":"Identifying Novel Psoriatic Disease Drug Targets Using a Genetics-Based Priority Index Pipeline.","date":"2021","source":"Journal of psoriasis and psoriatic arthritis","url":"https://pubmed.ncbi.nlm.nih.gov/35756599","citation_count":7,"is_preprint":false},{"pmid":"38129378","id":"PMC_38129378","title":"A novel autism-associated UBLCP1 mutation impacts proteasome regulation/activity.","date":"2023","source":"Translational psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/38129378","citation_count":6,"is_preprint":false},{"pmid":"40148470","id":"PMC_40148470","title":"Exploring new drug treatment targets for immune related bone diseases using a multi omics joint analysis strategy.","date":"2025","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/40148470","citation_count":4,"is_preprint":false},{"pmid":"38457337","id":"PMC_38457337","title":"Identification of molecular signatures defines the differential proteostasis response in induced spinal and cranial motor neurons.","date":"2024","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/38457337","citation_count":3,"is_preprint":false},{"pmid":"40736211","id":"PMC_40736211","title":"Genome-wide gene by sleepiness interaction analysis for sleep apnea.","date":"2026","source":"Sleep","url":"https://pubmed.ncbi.nlm.nih.gov/40736211","citation_count":2,"is_preprint":false},{"pmid":"40156024","id":"PMC_40156024","title":"Phosphatase UBLCP1 is required for the growth, virulence and mitochondrial integrity of Toxoplasma gondii.","date":"2025","source":"Parasites & vectors","url":"https://pubmed.ncbi.nlm.nih.gov/40156024","citation_count":0,"is_preprint":false},{"pmid":"41971766","id":"PMC_41971766","title":"Immune Cell-Mediated Retinoblastoma Development: Genetic and Molecular Mechanisms.","date":"2026","source":"International journal of genomics","url":"https://pubmed.ncbi.nlm.nih.gov/41971766","citation_count":0,"is_preprint":false},{"pmid":"42209436","id":"PMC_42209436","title":"Integrated Multi-Omics Strategies for Identifying Novel Therapies in Psoriasis.","date":"2026","source":"Bioinformatics (Oxford, England)","url":"https://pubmed.ncbi.nlm.nih.gov/42209436","citation_count":0,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":14067,"output_tokens":2064,"usd":0.036581,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":9049,"output_tokens":3021,"usd":0.060385,"stage2_stop_reason":"end_turn"},"total_usd":0.096966,"stage1_batch_id":"msgbatch_017qqVz33Ga63SCDwzb35XPb","stage2_batch_id":"msgbatch_01Scr2Ei9x4HJMiRGxwrmvLK","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2011,\n      \"finding\": \"UBLCP1 directly interacts with the 26S proteasome via its UBL domain and is exclusively localized in the nucleus. It dephosphorylates the 26S proteasome and inhibits proteasome activity in vitro. Knockdown of UBLCP1 in cells promotes 26S proteasome assembly and selectively enhances nuclear proteasome activity.\",\n      \"method\": \"Co-immunoprecipitation, in vitro phosphatase assay, siRNA knockdown with proteasome activity readout, nuclear localization by fractionation/imaging\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — in vitro enzymatic assay plus domain-mapping pulldown plus cellular KD with specific nuclear proteasome activity readout; foundational study by Dixon lab\",\n      \"pmids\": [\"21949367\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"NMR solution structure of the UBL domain of human UBLCP1 was determined; the domain contains a unique β3 strand and β3-α2 loop (instead of the canonical β4), and the positively charged residues of the β3-α2 loop mediate interaction with the C-terminal leucine-rich repeat-like domain of Rpn1 (a 19S regulatory particle subunit).\",\n      \"method\": \"NMR spectroscopy (high-resolution solution structure), backbone dynamics analysis, binding interaction mapping\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — high-resolution NMR structure with functional binding validation in single study\",\n      \"pmids\": [\"23667555\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"UBLCP1 acts as the proteasome-resident phosphatase that dephosphorylates Ser361 of Rpn1 (a 19S base subunit); PIM1/2/3 kinases phosphorylate Rpn1-S361, and UBLCP1 reverses this modification. Rpn1-S361 phosphorylation is required for proper 26S proteasome assembly, and loss of UBLCP1-regulated dephosphorylation alters this assembly step.\",\n      \"method\": \"CRISPR/Cas9 gene editing, quantitative mass spectrometry, human kinome screen, genetic code expansion for site-specific phosphorylation, co-immunoprecipitation of precursor complexes\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — multiple orthogonal methods (CRISPR, MS, kinome screen, genetic code expansion) establishing writer/eraser identity and mechanistic consequence for assembly\",\n      \"pmids\": [\"31843888\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"UBLCP1 contains a UBL domain and a CTD phosphatase domain, is localized in the nucleus, and can dephosphorylate GST-tagged RNA polymerase II CTD in vitro.\",\n      \"method\": \"Transient transfection with subcellular localization imaging (COS-7 cells), in vitro phosphatase assay with GST-CTD substrate\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1–3 / Weak — in vitro phosphatase activity shown but single lab, limited mechanistic follow-up; nuclear localization by transfection imaging\",\n      \"pmids\": [\"15883030\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"A small-molecule inhibitor (compound 13, IC50 = 1.0 µM) targeting both the UBLCP1 phosphatase active site and an adjacent binding pocket selectively inhibits UBLCP1 and, in cells, inhibits UBLCP1 function and upregulates nuclear proteasome activity.\",\n      \"method\": \"Salicylic acid fragment-based library screening, IC50 determination, selectivity panel against multiple phosphatase families, cellular proteasome activity assay\",\n      \"journal\": \"Bioorganic & medicinal chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — active-site-directed inhibitor with selectivity profiling and cellular functional readout, single lab\",\n      \"pmids\": [\"25907364\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"UBLCP1, via its UBL domain, activates latent 26S proteasomes by stimulating peptide hydrolysis two- to fivefold; the UBL domain is specifically required for the increase in ATPase activity, while peptide hydrolysis stimulation can also occur independent of the UBL domain.\",\n      \"method\": \"In vitro proteasome activity assays (peptide hydrolysis, ATPase), UBL domain deletion constructs, purified protein reconstitution\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro reconstitution with domain-deletion mutagenesis, multiple activity readouts, single lab\",\n      \"pmids\": [\"32071216\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"A truncating deletion in UBLCP1 exon 10 (generating a premature stop codon in the phosphatase domain) leads to decreased UBLCP1 protein expression, increased proteasome activity, decreased ubiquitinated protein levels, and downregulation of other proteasome subunits in patient-derived fibroblasts. Restoration of full-length UBLCP1 via gentamicin-promoted read-through rescues function.\",\n      \"method\": \"Whole exome sequencing, patient-derived fibroblast functional assays, proteasome activity assay, ubiquitinated protein levels, MG132 rescue experiment, gentamicin read-through restoration\",\n      \"journal\": \"Translational psychiatry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — patient-derived loss-of-function with multiple biochemical readouts and pharmacological rescue, single study\",\n      \"pmids\": [\"38129378\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Ublcp1 was identified as an iCrMN (induced cranial motor neuron)-specific regulator of nuclear 26S proteasome activity; cranial motor neurons express higher levels of Ublcp1 relative to spinal motor neurons and show higher 26S (but not 20S) proteasome activity.\",\n      \"method\": \"Quantitative transcriptome and proteome profiling of induced motor neurons, 26S vs 20S proteasome activity assays, cell-type comparison\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Weak — proteasome activity assay in cell-type comparison with Ublcp1 identified as regulator, single study, limited mechanistic follow-up of UBLCP1 specifically\",\n      \"pmids\": [\"38457337\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"UBLCP1 is a nuclear phosphatase that binds the 26S proteasome via its UBL domain (which contacts the Rpn1 subunit) and inhibits proteasome activity by dephosphorylating key regulatory phosphosites including Rpn1-Ser361, thereby restraining 26S assembly and nuclear proteasome activity; paradoxically, its UBL domain can also directly activate latent proteasomes by stimulating both peptide hydrolysis and ATPase activity.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"UBLCP1 is a nuclear proteasome-resident phosphatase that restrains nuclear 26S proteasome activity by dephosphorylating regulatory phosphosites on the 19S regulatory particle [#0]. It engages the proteasome through its UBL domain, whose unique β3 strand and positively charged β3-α2 loop directly contact the C-terminal leucine-rich repeat-like domain of the Rpn1 subunit [#1]. Mechanistically, UBLCP1 functions as the eraser for Rpn1-Ser361, a site written by PIM1/2/3 kinases that is required for proper 26S assembly; by reversing this phosphorylation UBLCP1 antagonizes 26S assembly, and its depletion promotes assembly and selectively enhances nuclear proteasome activity [#0, #2]. The catalytic CTD phosphatase domain can also dephosphorylate the RNA polymerase II CTD in vitro [#3]. Paradoxically, the UBL domain directly stimulates latent 26S proteasomes, increasing peptide hydrolysis two- to fivefold and being specifically required for stimulation of ATPase activity, indicating a dual regulatory output beyond its phosphatase activity [#5]. A small-molecule inhibitor targeting the phosphatase active site and an adjacent pocket selectively blocks UBLCP1 and upregulates nuclear proteasome activity in cells [#4]. A truncating UBLCP1 deletion in patient-derived fibroblasts reduces UBLCP1 protein, elevates proteasome activity, and lowers ubiquitinated protein levels, with read-through restoration rescuing function, linking loss of UBLCP1 to a human phenotype [#6].\",\n  \"teleology\": [\n    {\n      \"year\": 2005,\n      \"claim\": \"Established UBLCP1's domain architecture and catalytic potential before its physiological substrate was known, identifying a nuclear protein combining a UBL domain with a CTD phosphatase domain capable of dephosphorylating RNA Pol II CTD in vitro.\",\n      \"evidence\": \"Subcellular localization imaging in COS-7 cells and in vitro phosphatase assay with GST-CTD substrate\",\n      \"pmids\": [\"15883030\"],\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"\",\n      \"gaps\": [\"RNA Pol II CTD demonstrated only in vitro, with no cellular substrate established\", \"no link to the proteasome at this stage\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Defined UBLCP1's core function as a nuclear proteasome phosphatase that negatively regulates nuclear 26S proteasome activity and assembly, resolving what its phosphatase activity acts upon physiologically.\",\n      \"evidence\": \"Co-immunoprecipitation, in vitro phosphatase assay, siRNA knockdown with nuclear proteasome activity readout, and nuclear localization by fractionation/imaging\",\n      \"pmids\": [\"21949367\"],\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"\",\n      \"gaps\": [\"specific proteasome phosphosite substrate not yet identified\", \"structural basis of UBL-proteasome contact not defined\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Provided the structural basis for proteasome engagement, showing how a non-canonical UBL fold uses a charged β3-α2 loop to bind a specific 19S subunit.\",\n      \"evidence\": \"High-resolution NMR solution structure of the UBL domain with binding interaction mapping to Rpn1 LRR-like domain\",\n      \"pmids\": [\"23667555\"],\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"\",\n      \"gaps\": [\"full-length enzyme-proteasome complex structure not determined\", \"does not address how binding positions the catalytic domain on its substrate\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Demonstrated UBLCP1 is pharmacologically tractable and confirmed its inhibitory role on nuclear proteasome activity in cells through chemical inhibition.\",\n      \"evidence\": \"Fragment-based screening yielding an active-site/adjacent-pocket inhibitor, selectivity profiling, and cellular proteasome activity assay\",\n      \"pmids\": [\"25907364\"],\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"\",\n      \"gaps\": [\"single lab\", \"no in vivo validation of the inhibitor\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Identified the precise phospho-substrate and the writer/eraser logic, establishing Rpn1-Ser361 as the UBLCP1 dephosphorylation target reversing PIM kinase phosphorylation to control 26S assembly.\",\n      \"evidence\": \"CRISPR/Cas9 editing, quantitative mass spectrometry, human kinome screen, genetic code expansion for site-specific phosphorylation, and Co-IP of precursor complexes\",\n      \"pmids\": [\"31843888\"],\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"\",\n      \"gaps\": [\"whether additional proteasome phosphosites are UBLCP1 substrates not resolved\", \"in vivo physiological context of the PIM-UBLCP1 axis not addressed\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Revealed a paradoxical second activity, showing the UBL domain directly stimulates latent proteasome peptide hydrolysis and is specifically required for ATPase stimulation, decoupling proteasome activation from the phosphatase function.\",\n      \"evidence\": \"In vitro peptide hydrolysis and ATPase assays with UBL domain deletion constructs and purified protein reconstitution\",\n      \"pmids\": [\"32071216\"],\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"\",\n      \"gaps\": [\"how phosphatase-dependent inhibition and UBL-dependent activation are reconciled in cells not resolved\", \"single lab in vitro reconstitution\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Linked UBLCP1 loss of function to a human disease phenotype, showing a truncating deletion reduces protein, elevates proteasome activity, and is rescuable by read-through.\",\n      \"evidence\": \"Whole exome sequencing and patient-derived fibroblast functional assays with gentamicin read-through restoration\",\n      \"pmids\": [\"38129378\"],\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"\",\n      \"gaps\": [\"single study\", \"genotype-phenotype causality at the organismal level not fully established\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Placed UBLCP1 in a cell-type-specific context, identifying it as a cranial motor neuron-specific regulator that tunes nuclear 26S (not 20S) proteasome activity.\",\n      \"evidence\": \"Quantitative transcriptome/proteome profiling of induced motor neurons and 26S vs 20S proteasome activity comparison\",\n      \"pmids\": [\"38457337\"],\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"\",\n      \"gaps\": [\"mechanistic basis of cell-type selectivity not defined\", \"limited mechanistic follow-up specific to UBLCP1\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How the inhibitory phosphatase activity and the activating UBL-domain function are integrated to set net nuclear proteasome output in a physiological cell context remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"\",\n      \"gaps\": [\"no model reconciling dual inhibitory/activating outputs in vivo\", \"regulation of UBLCP1 itself (upstream signals controlling its activity) uncharacterized\", \"full enzyme-proteasome complex structure not determined\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0016787\", \"supporting_discovery_ids\": [0, 2, 3]},\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [0, 2, 3]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [0, 5]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [0, 3]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-392499\", \"supporting_discovery_ids\": [0, 2]}\n    ],\n    \"complexes\": [\"26S proteasome\"],\n    \"partners\": [\"PSMD2\", \"PIM1\", \"PIM2\", \"PIM3\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":7,"faith_total":7,"faith_pct":100.0}}